Bridgeway Capital Management LLC Makes New Investment in Mural Oncology plc (NASDAQ:MURA)

Bridgeway Capital Management LLC purchased a new position in Mural Oncology plc (NASDAQ:MURA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 29,300 shares of the company’s stock, valued at approximately $94,000. Bridgeway Capital Management LLC owned about 0.17% of Mural Oncology as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in Mural Oncology in the 4th quarter valued at about $181,000. Virtu Financial LLC purchased a new stake in Mural Oncology in the fourth quarter worth approximately $129,000. Renaissance Technologies LLC boosted its stake in Mural Oncology by 17.4% in the fourth quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock worth $768,000 after buying an additional 35,403 shares in the last quarter. Northern Trust Corp boosted its stake in Mural Oncology by 22.0% in the fourth quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock worth $129,000 after buying an additional 7,197 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Mural Oncology in the fourth quarter worth approximately $68,000. 80.21% of the stock is owned by hedge funds and other institutional investors.

Mural Oncology Stock Performance

Shares of NASDAQ:MURA opened at $2.66 on Wednesday. The stock has a market capitalization of $45.93 million, a price-to-earnings ratio of -0.29 and a beta of 3.91. The stock’s 50-day simple moving average is $2.43 and its two-hundred day simple moving average is $3.26. Mural Oncology plc has a 52-week low of $0.95 and a 52-week high of $4.74.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter in the previous year, the firm earned ($3.57) earnings per share. As a group, equities analysts forecast that Mural Oncology plc will post -7.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MURA. Raymond James lowered Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective for the company. in a research note on Tuesday, March 25th. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a report on Tuesday, March 25th. Morgan Stanley downgraded Mural Oncology from an “overweight” rating to an “equal weight” rating in a report on Tuesday, March 25th. Finally, HC Wainwright reduced their price target on Mural Oncology from $18.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, March 26th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.